Novo Nordisk BLA Update: US FDA Review Ongoing
Novo Nordisk announced that the US Food and Drug Administration (FDA) has informed the company that the review of the Biologics License Application (BLA) for denecimig, a treatment for haemophilia A, is still ongoing. The FDA has not yet communicated a specific timeline for the completion of the review.